CAS 847591-62-2

(6S,9aS)-Hexahydro-6-[(4-hydroxyphenyl)methyl]-8-(1-naphthalenylmethyl)-4,7-dioxo-N-(phenylmethyl)-2H-pyrazino[1,2-a]pyrimidine-1(6H)-carboxamide

Description:

The chemical substance with the name "(6S,9aS)-Hexahydro-6-[(4-hydroxyphenyl)methyl]-8-(1-naphthalenylmethyl)-4,7-dioxo-N-(phenylmethyl)-2H-pyrazino[1,2-a]pyrimidine-1(6H)-carboxamide" and CAS number "847591-62-2" is a complex organic compound characterized by its multi-ring structure, which includes a pyrazino-pyrimidine core. This compound features multiple functional groups, including a carboxamide and hydroxyl group, contributing to its potential biological activity. The presence of aromatic rings, such as the naphthalene and phenyl groups, suggests possible interactions with biological targets, making it of interest in medicinal chemistry. Its stereochemistry, indicated by the specific configuration at the 6 and 9a positions, may influence its pharmacological properties and interactions. The compound's dioxo functionality may also play a role in its reactivity and stability. Overall, this substance is likely to be investigated for its therapeutic potential, particularly in areas related to cancer or other diseases, due to its structural complexity and the presence of bioactive moieties.

Formula: C₃₃H₃₂N₄O₄

Synonyms:

• Icg-001

PRI 724

CAS: 847591-62-2

Formula: C₃₃H₃₂N₄O₄

Purity: 98%

Color and Shape: Solid

Molecular weight: 548.6316

Ref: IN-DA00G3OL

ICG001

CAS: 847591-62-2

ICG001

Purity: ≥98%

Molecular weight: 548.63g/mol

Ref: 54-BUP08061

ICG001

CAS: 847591-62-2

ICG001 antagonizes Wnt signaling, binds CBP with 3 μM IC50, not p300.

Formula: C₃₃H₃₂N₄O₄

Purity: 99.06% - 99.95%

Color and Shape: Solid

Molecular weight: 548.63

Ref: TM-T2237

(S,S)-ICG 001

Controlled Product

CAS: 847591-62-2

Formula: C₃₃H₃₂N₄O₄

Color and Shape: Neat

Molecular weight: 548.632

Ref: TR-I163800

ICG 001

CAS: 847591-62-2

ICG-001 is a small molecule inhibitor that specifically targets the Wnt/β-catenin signaling pathway. This compound is derived from a rational drug design approach aimed at disrupting the interaction between β-catenin and its coactivator cyclic AMP response element-binding protein (CBP). By selectively inhibiting this interaction, ICG-001 effectively downregulates the transcriptional activity mediated by β-catenin without affecting its structural role in cell adhesion.

Formula: C₃₃H₃₂N₄O₄

Purity: Min. 95%

Molecular weight: 548.63 g/mol

Ref: 3D-XIB59162